Efficacy, Safety, and Tolerability of Eslicarbazepine Acetate in the Recurrence Prevention of Bipolar I Disorder

NCT01825837 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

104

Enrollment

INDUSTRY

Sponsor class

Conditions

Bipolar I Disorder

Interventions

DRUG: BIA 2-093 1800 mg once daily [Group 1 (Part II)]
DRUG: BIA 2-093 900 mg once daily [Group 2 (Part II)]
DRUG: BIA 2-093 300 mg once daily [Group 3 (Part II)]
DRUG: BIA 2-093 900 mg (Part I)

Sponsor

Bial - Portela C S.A.